188 related articles for article (PubMed ID: 28434649)
1. Immune oncology in hepatocellular carcinoma-hype and hope.
Wörns MA; Galle PR
Lancet; 2017 Jun; 389(10088):2448-2449. PubMed ID: 28434649
[No Abstract] [Full Text] [Related]
2. Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.
Gadaleta-Caldarola G; Divella R; Mazzocca A; Infusino S; Ferraro E; Filippelli G; Daniele A; Sabbà C; Abbate I; Brandi M
Future Oncol; 2015; 11(16):2263-6. PubMed ID: 26260805
[No Abstract] [Full Text] [Related]
3. Treatment of intermediate-stage hepatocellular carcinoma.
Finn RS
Clin Adv Hematol Oncol; 2015 Aug; 13(8):501-3. PubMed ID: 26351811
[No Abstract] [Full Text] [Related]
4. The role of sorafenib in hepatocellular carcinoma.
Gholam P
Clin Adv Hematol Oncol; 2015 Apr; 13(4):232-4. PubMed ID: 26352581
[No Abstract] [Full Text] [Related]
5. Sorafenib in hepatocellular carcinoma.
Josephs DH; Ross PJ
Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
[TBL] [Abstract][Full Text] [Related]
6. [Hepatocellular carcinoma - long-term treatable disease].
Fínek J
Klin Onkol; 2012; 25(4):287-9. PubMed ID: 22920170
[TBL] [Abstract][Full Text] [Related]
7. Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?
Faivre S; de Gramont A; Raymond E
Target Oncol; 2016 Aug; 11(4):565-7. PubMed ID: 26996978
[No Abstract] [Full Text] [Related]
8. Hepatocellular carcinoma: The beginning of a long journey.
Cascinu S
Dig Liver Dis; 2009 Oct; 41(10):707-8. PubMed ID: 19699696
[No Abstract] [Full Text] [Related]
9. Brivanib and FOLFOX in hepatocellular carcinoma: finding the common themes among negative trials.
Kelley RK
J Clin Oncol; 2013 Oct; 31(28):3483-6. PubMed ID: 23980088
[No Abstract] [Full Text] [Related]
10. Reply to M. Bouattour et al.
Cainap C; McKee MD; Ricker JL
J Clin Oncol; 2015 Aug; 33(22):2486. PubMed ID: 26033815
[No Abstract] [Full Text] [Related]
11. Negative Trials for Foreseeable Safety Reasons in Advanced Hepatocellular Carcinoma: How Long Are We Going to Take Lightly Pharmacokinetics of Tyrosine Kinase Inhibitors?
Bouattour M; Rousseau B; Wassermann J; Payancé A; Huillard O
J Clin Oncol; 2015 Aug; 33(22):2484-5. PubMed ID: 26033820
[No Abstract] [Full Text] [Related]
12. Sorafenib for liver cancer: the horizon broadens.
Johnson P; Billingham L
Lancet Oncol; 2009 Jan; 10(1):4-5. PubMed ID: 19111238
[No Abstract] [Full Text] [Related]
13. Hepatocellular carcinoma and sorafenib: too many resistance mechanisms?
Berasain C
Gut; 2013 Dec; 62(12):1674-5. PubMed ID: 23481262
[No Abstract] [Full Text] [Related]
14. Sorafenib in advanced hepatocellular carcinoma.
Palmer DH
N Engl J Med; 2008 Dec; 359(23):2498; author reply 2498-9. PubMed ID: 19065750
[No Abstract] [Full Text] [Related]
15. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma.
Chen J; Jin R; Zhao J; Liu J; Ying H; Yan H; Zhou S; Liang Y; Huang D; Liang X; Yu H; Lin H; Cai X
Cancer Lett; 2015 Oct; 367(1):1-11. PubMed ID: 26170167
[TBL] [Abstract][Full Text] [Related]
16. Brivanib for hepatocellular carcinoma trials: selection bias from barcelona clinic liver cancer stage?
Qi X; Jia J; Fan D; Han G
J Clin Oncol; 2014 Mar; 32(9):968. PubMed ID: 24516020
[No Abstract] [Full Text] [Related]
17. [Hepatocellular carcinoma].
Yamashita T; Arai K; Kaneko S
Nihon Rinsho; 2010 Oct; 68(10):1861-5. PubMed ID: 20954330
[TBL] [Abstract][Full Text] [Related]
18. Sustained complete remission of advanced hepatocellular carcinoma with sorafenib therapy.
Azmi AN; Chan WK; Goh KL
J Dig Dis; 2015 Sep; 16(9):537-40. PubMed ID: 26147446
[No Abstract] [Full Text] [Related]
19. Prognostic Factors Associated with Postprogression Survival in Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib Not Eligible for Second-Line Regorafenib Treatment.
Kuzuya T; Ishigami M; Ishizu Y; Honda T; Hayashi K; Ishikawa T; Nakano I; Hirooka Y; Goto H
Oncology; 2018; 95(2):91-99. PubMed ID: 29723866
[TBL] [Abstract][Full Text] [Related]
20. Regorafenib: a newly approved drug for advanced hepatocellular carcinoma.
Kyrochristos ID; Ziogas DE; Roukos DH
Future Oncol; 2017 Aug; 13(19):1665-1668. PubMed ID: 28613123
[No Abstract] [Full Text] [Related]
[Next] [New Search]
